Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Related

470.040
+0.9290.20%
Number of Gainers:16
Number of Losers:30
Number of Flat:5
PE:- -
High:471.208
Open:468.227
Low:465.418
Close:469.111
Volume:122.61M
Turnover:3.60B
Market Cap:2.95T
Float Cap:2.07T

Loading ...

Poly Property Services FY26 H1 Profit Rises 4.3% to RMB 942.7 Million; Revenue Climbs 5.2% to RMB 8.83 Billion

Reuters
·
Aug 25

SUNAC Shares Surge Over 9% in Morning Trade Following Strategic Shift to Asset Management and Operations

Stock News
·
Aug 25

Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results

Stock News
·
Aug 25

Hong Kong Stock Market Update | JXR Surges Over 4% in Morning Trade on Strong H1 Results and Strategic Focus on VIP and International Expansion

Stock News
·
Aug 25

The Bell Rings, $170 Billion Vanishes: Why Isn't Wang Xingxing Smiling?

Deep News
·
Aug 25

Is Xtep International Holdings (SEHK:1368) Undervalued After Its Shanghai Running Tech Launch?

Simply Wall St.
·
Aug 25

Interim Results Analysis: PEIJIA-B's Core AR Product Exceeds Expectations, Reinforcing Profitability Signals and Investment Certainty

Stock News
·
Aug 25

RemeGen Swings to Profit in H1 as Revenue Surges Fivefold

MT Newswires Live
·
Aug 25

Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases

THOMSON REUTERS
·
Aug 25

Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy

Stock News
·
Aug 25

Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases

Reuters
·
Aug 25

Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia

THOMSON REUTERS
·
Aug 25

Wuxi AppTec Resolves DEL Platform Security Breach, Continues Investigation With Cyber Specialists

Stock News
·
Aug 24

mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence

Deep News
·
Aug 24

China's Shanghai INT Medical Instruments H1 Revenue Jumps on Acquisitions

Reuters
·
Aug 24

China's Peijia Medical H1 Revenue Jumps on Transcatheter Valve Therapeutics Growth

Reuters
·
Aug 24

Peijia Medical H1 Revenue RMB 424.5 Million

THOMSON REUTERS
·
Aug 24

Press Release: Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Dow Jones
·
Aug 24

JXR Buys Back 1.346 Million Shares on August 24 for HK$2.999 Million

Stock News
·
Aug 24

China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth

Reuters
·
Aug 24